Member Info for NoOneKnows

Time to wait and see but this does look a good fit for UPSA in giving them a relatively cheap entry onto the main market.

Funded for an interesting time over the next 12 months.

UPSA(via AMG) share listed for the first time could be a very interesting prospect.

Just gambling on the deal going through really... if it does the sp should be £2.50-£3 or more... to buy or not to buy ?

Comment worth noting from the article... "aptamers offer many advantages over protein therapeutics and are expected to become an increasingly important therapeutic modality in the bio/pharmaceutical industry’s future."

Reading the rns it looks a straight buy.

The sp will be multiples of this in a couple of years... patience is key.

It has seemed to be the trend with Aptamer since the .2 low(2023 I think)... it shoots up and then drops back a bit but the longer term trend has been very good and in my opinion will go a lot further north yet.

In other news.. GF attended a jewelery show :/

We know with how slow progress is there will be another raise before any gold is brought and out and processed. We also know GROC will likely need to raise more money so Albas % in GROC is likely to drop further. I think losing 2 people with so much experience (Kobus amd MA ) says a lot about the prospects. What AI says about Motzfeld doesn't fill me with confidence... AI "Motzfeldt presents significant logistical challenges for mining due to its remote location in Greenland, which requires costly infrastructure and transportation, as well as the presence of a rugged Arctic terrain and harsh climate. Although the deposit itself has considerable potential for rare earth elements, particularly tantalum, and is a known geological resource, the economic viability of mining there is hampered by the high costs associated with overcoming these environmental and infrastructural hurdles"

Its not just about Unilever they have so much going on.. Alzheimers test and Liver fibrosis treatment being 2 more stand out projects.

No share goes up in a straight line and 6 weeks ago I'd have taken being over 1p now. Still a long way to go and as several regular posters have said before patience is key and will be rewarded.

A quick test for Sepsis would be great news as its often misdiagnosed as the early symptoms resemble other infections.

02-Sep-25 15:54:37 1.30 2,700,337 Unknown* 1.25 1.30 35.10k

I assume any work done successfully could lead to another licensing deal. I think news will be coming pretty regularly as they have so much going on and I am pleased to be part of it in a small way.

Share Options

The Company intends to award share options to retain and incentivise the Directors and employees. The number of share options granted will be up to 25 per cent. of the issued share capital as enlarged by the Fundraise. These options will vest subject to stretching performance targets and will vest and exercise as follows:

(a) 33% on the share price having remained at or above 7 times the Issue Price for at least 3 months and exercisable 6 months following vesting;

(b) 33% on the share price having remained at or above 10 times the Issue Price for at least 3 months and exercisable 12 months following vesting; and

(c) 33% on the share price having remained at or above 12.5 times the Issue Price for at least 3 months and exercisable 24 months following vesting.

All in the money share options would vest in the event that the Company is acquired (or in the event of that a person or group shall have acquired or entered into a definitive binding agreement to acquire more than 50% of the issued share capital of the Company or assets of the Company or its subsidiaries representing more than 50% of the consolidated earning power of the Company and its subsidiaries taken as a whole).

The options will have an exercise price equal to the Issue Price.

The award of these options will be a related party transaction under the AIM Rules and will therefore be subject to the independent directors considering the terms of the options and reaching an opinion, having consulted with SPARK, as its nominated adviser, that the terms of the transaction are fair and reasonable insofar as its shareholders are concerned. It is currently envisaged that these options will be awarded following the Second Admission.

In October 2023 share options were awarded to Directors and staff with an exercise price of 1 penny. Awardees of that option scheme will forfeit their share options on acceptance of this latest award.

The issue price was .2 so options at 1.4, 2.0 and 2.5

Freddie hat was your post I think

Https://www.researchandmarkets.com/reports/5782939/aptamers-market-report#tag-pos-2

From the site Freddie posted.

"The aptamers market size has grown exponentially in recent years. It will grow from $2.65 billion in 2024 to $3.28 billion in 2025 at a compound annual growth rate (CAGR) of 23.6%. The growth in the historic period can be attributed to need for high-specificity binders, therapeutic potential, rise in personalized medicine, potential for therapeutic areas, antibody alternatives, diagnostic point-of-care (POC) devices".

With this sustained upward trend with the sp you have to think there is some serious money being filtered in and they won't be worrying about the day to day sp they will be looking at this as long term .